The balance of evidence from observational studies suggests that elevated homocysteine levels are associated with increased risk of carotid artery disease and stroke. There is however a paucity of prospective studies. There are also concerns regarding confounding due to factors associated with hyperhomocysteinemia, including renal impairment, an atherogenic diet and cigarette smoking. Homozygosity for a defective thermolabile variant of MTHFR, a common genetic polymorphism which results in hyperhomocysteinemia, has not been consistently linked with stroke or other vascular disease. There is a need for additional prospective studies with data on relevant confounders, sufficient power to characterise the form of the association between homocysteine concentrations and stroke risk, whether linear or threshold, and power to study interactions between homocysteine, other dietary markers and established stroke risk factors such as smoking and
Introduction
Homocysteine is a sulphur-containing amino acid produced by demethylation of dietary methionine, an essential amino acid. It is now almost three decades since McCully first linked elevated plasma homocysteine concentrations with vascular disease on the basis of clinical observations in patients with homocysteinuria. 1 Homocysteinuria results from one of several rare genetic disorders of enzymes involved in homocysteine metabolism. It is characterised by markedly elevated concentrations of homocysteine in plasma and high risk of atherothrombotic events, including myocardial infarction and stroke in early adolescence and even in childhood. 2 It is estimated that approximately 50% of patients with untreated homocysteinuria will have a major vascular event before the age of 30 years. 2 Studies in humans and in animal models have linked hyperhomocysteinemia to oxidative damage to vascular endothelium, proliferation of vascular smooth muscle cells, lipid peroxidation and oxidation of low-density lipoprotein. 3 In recent years it has emerged that moderately elevated plasma homocysteine concentrations are common in the general population and that moderate hyperhomocysteinaemia may also be a risk factor for vascular disease. 4 Correspondence: Professor Ivan J Perry Received 23 July 1998; revised and accepted 6 January 1999 hypertension. Similarly, the evidence linking hyperhomocysteinemia with hypertension is limited and inconsistent. Given the biological mechanisms proposed in support of the homocysteine-CVD hypothesis, one would predict a positive association between homocysteine and blood pressure. There is a need to address this hypothesis directly in studies with reliable measurements of both homocysteine and blood pressure. Ultimately, the case for a causal role for elevated homocysteine levels in vascular disease, including hypertension and stroke, will depend on data from randomised controlled trials of homocysteine lowering interventions. Given the high prevalence of hyperhomocysteinemia in apparently well nourished populations and the tendency for homocysteine concentrations to increase with age, modest effects of homocysteine on stroke risk will have profound implications for public health Moderate hyperhomocysteinaemia reflects less critical genetic defects combined with deficiency of nutritional co-factors required for homocysteine metabolism, folate, vitamin B12 and vitamin B6. 5, 6 Folate intake is the key nutritional determinant of homocysteine concentrations in the general population and it appears that dietary supplementation, at modest dose levels (circa 400 g folate daily), effectively lowers homocysteine concentrations, regardless of the origin of hyperhomocysteinaemia. 4 Thus, the putative link between total homocysteine (tHcy) concentrations in blood and vascular disease end-points has clear and important implications for basic science, clinical practice and public health. (Hcy refers to homocysteine with reduced or oxidised sulphydryl group and tHcy to protein bound and non-protein bound moieties.)
As we approach the 30th anniversary of McCully's classic paper it may now be timely to consider the current status of this hypothesis. Specifically, this review will consider the evidence linking raised homocysteine concentrations to risk of stroke and the subsidiary question of whether hyperhomocysteinemia is implicated in the development of essential hypertension?
tHcy and cardiovascular disease
The balance of evidence from observational studies suggests that elevated homocysteine levels are associated with increased risk of vascular disease, including peripheral vascular disease, ischaemic heart disease and stroke. 4 Hyperhomocysteinaemia has also been linked with deep venous thrombosis, 7 vascular disease in SLE 8 and tentatively with a number of other conditions including dementia 9,10 and pre-eclampsia. 11, 12 There are however problems with the current data. The majority of studies to-date have been cross-sectional or retrospective case-control studies and are susceptible to bias if, as has been suggested, tHcy levels rise as a consequence of vascular disease or after an acute event. In this context it should be noted that renal impairment is an established cause of hyperhomocysteinaemia. 13 There are additional concerns regarding unmeasured and residual confounding due to dietary and other lifestyle factors associated with hyperhomocysteinaemia. 14, 15 The findings from the small number of prospective studies that have addressed associations between tHcy concentrations and incident coronary heart diseases (CHD) or stroke are inconsistent [16] [17] [18] [19] [20] [21] [22] Homozygosity for a defective thermolabile variant of MTHFR, a common genetic polymorphism which results in hyperhomocysteinemia, has not been consistently linked with cardiovascular disease endpoints. 23, 24 Although the importance of gene markers will vary depending on relevant environmental exposures, diet in this instance, the findings from gene association studies conducted to-date are distinctly unimpressive. The biological plausibility of the tHcy-vascular disease hypothesis rests partially on studies that have used unphysiologically high doses of homocysteine. Finally and crucially, we lack data from randomised controlled trials showing that tHcy lowering interventions prevent vascular end-points.
tHcy and stroke
These problems are well illustrated in the data on tHcy concentrations and risk of stroke (Table 1) . Boushey and colleagues have reported on a metaanalysis of 27 observational studies, published before 1994, relating tHcy concentrations to atherosclerotic vascular disease, of which 11 studies addressed the association between homocysteine and risk of stroke. 4 Nine case-control studies provided support for the hypothesis that homocysteine is an independent risk factor for stroke while two prospective studies were negative. The summary estimate of the odds ratio for cerebrovascular disease in persons with elevated homocysteine levels (generally defined as above the 95th percentile for the control group or above 2s.d. of the control mean), was 2.5 (95% CI, 2.0 to 3.0). In this metaanalysis the study design of seven of the nine case control studies was categorised as 'other case-control'. This 'other case-control' study category includes a high proportion of small studies based on controls recruited from either ill-defined screening exercises or volunteer samples. In a number of these smaller case-control studies, the method of recruitment of cases was also ill defined. The Boushy metaanalysis includes data from the European Concerted Action Project which had been presented in abstract form in 1994. This study contributed 214 of the total of 566 stroke cases included in the meta-analysis. Even in this carefully conducted study, less than one half of controls were recruited from random community samples and one-sixth were hospital employees. For proponents of the homocysteinestroke hypothesis it was somewhat disconcerting that the two prospective studies included in this meta-analysis, both based on a nested case-control design, were negative. 18, 19 In the US physicians study a weak non-significant association was observed between total homocysteine concentrations and ischaemic stroke 19 and in a propective study from the North Karelia Project, no association with either myocardial infarction or stroke was observed. 18 It should be emphasised however that these studies may have lacked power to address the homocysteine-stroke hypothesis as both were based on populations with relatively few individuals in the upper tail of the skewed tHcy distribution.
European concerted action project
Data from the European Concerted Action Project study of homocysteine and risk of atherosclerotic vascular disease were published in full in 1977. 25 As one would expect, the findings from this large case-control study involving a total of 750 cases of atherosclerotic vascular disease (cardiac, cerebral and peripheral) and 800 controls of both sexes, younger than 60 years, are largely consistent with the earlier meta-analysis to which it had made a substantial contribution. The relative risk of stroke was increased more than two-fold in the top fifth of both the fasting and post-load total homocysteine distribution, relative to the bottom four-fifths with minimal attenuation on adjustment for major established risk factors. There was also evidence of a modest dose response relation between total homocysteine level and risk of vascular disease including stroke across the distribution of homocysteine. The level of vascular disease risk in the upper quintile of homocysteine was equivalent to that associated with hypercholesterolemia or cigarette smoking and interaction effects were noted with risk amplified in the presence of either cigarette smoking or hypertension.
Recent prospective studies
In prospective data from the British Regional Heart study cohort, a positive, graded linear relation between serum total homocysteine concentration and risk of stroke was observed, with an over twofold increased risk in the fourth quartile of distribution, relative to the first. 20, 21 More recently, in the Rotterdam cohort, a positive association between homocysteine and stroke has also been reported. 22 In this study, however, the relation was non-linear with a two-fold increase in risk in the upper quintile relative to rest of the distribution. Additional support for the homocysteine stroke hypothesis is provided by cross-sectional studies, showing independent associations between homocysteine concentrations and carotid atherosclerosis. For instance in a study of 1041 elderly participants in the Framingham Heart Study, Selhub and colleagues observed a significant association between plasma homocysteine and the prevalence of significant extracranial carotid artery stenosis in men and a similar, although weaker, association in women. 26 In this study the association between homocysteine and carotid artery disease was linear with abnormal findings at homocysteine concentrations regarded as within the normal range. Plasma concentrations of folate and pyridoxal-5Ј-phosphate and the level of dietary folate intake were inversely associated with carotid artery stenosis after adjustment for age, sex and other risk factors. Similarily in the ARIC study, the odds ratio for having a thickened carotid artery wall was increased over three-fold among subjects in the top quintile of plasma homocysteine levels compared with those in the bottom quintile. This association was independent of a wide range of established cardiovascular disease risk factors. 27 
Confounding
Clearly, in studies showing continuous associations between tHcy and carotid atherosclerosis there is less potential for bias due to event related dietary change or renal impairment than in cross-sectional or conventional case-control studies with symptomatic disease as the end-point. Nonetheless, concerns about confounding remain. For instance the Framingham study of tHcy and carotid artery stenosis 26 and in most (although not all) 20 of the casecontrol and prospective studies of tHcy and major CVD end-points the data were not adjusted for serum creatinine or other measures of renal impairment. Homocysteine levels are higher in men than in women and increase with age due to declining renal function. 13 Significant associations are also described with cigarette smoking, serum cholesterol levels and physical inactivity. 14, 15 In the Hordarland study, a cross-sectional study of homocysteine and established vascular risk factors, sex, age, folate intake, smoking status and coffee consumption were the strongest determinants of plasma homocysteine concentration in multivariate analysis which did not include serum creatinine. 14, 15 These associations between hyperhomocysteinaemia and established vascular risk factors are likely to reflect, at least in part, links with common underlying dietary and lifestyle factors, in particular, a diet high in saturated fat with inadequate folate intake from fruit and vegetables. Given this background of multiple inter-correlated dietary and lifestyle exposures and physiological measures, all measured with variable reliability, it is clear that the question of the independent effects of homocysteine concentration on stroke or other vascular end-points must be approached with caution. 28 The difficulties in this area are well illustrated in further data from the European Concerted Action Project 29 and in a recent report from the ARIC study. 30 In the European Concerted Action Project, concentrations of red cell folate below the lowest 10th percentile and plasma vitamin B6 below the lowest 20th percentile for control subjects were associated with increased risk of vascular disease. As one would expect, the association with folate was explained in part by increased homocysteine levels. In contrast, however, the relation between vitamin B6 and atherosclerosis was independent of homocysteine levels. 29 This finding, of an apparently independent effects of vitamin B6 on vascular risk in the European Concerted Action Project data, emphasises the need for caution in ascribing independent effects of homocysteine on vascular disease in studies with limited dietary exposure data. Similarily, in prospective data from the ARIC study, plasma pyridoxal-5Ј-phosphate but not plasma tHcy was associated with CHD events in multivariate analysis.
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Homocysteine and blood pressure
It would seem reasonable to predict an association between tHcy and blood pressure in the general population, given the well described associations between hyperhomocysteinaemia and renal impairment 13 and the postulated effects of homocysteine on vascular endothelial function and proliferation of vascular smooth muscle cells. 3 In the Hordaland Study, a significant positive associations with blood pressure was observed.
14 However this association was weak and was confined to younger men and women. In this study, tHcy was not significantly associated with blood pressure in a sub-group of 1386 men and 1932 women aged 65 to 74 years. Similarly, in data from the UK National Diet and Nutrition Survey, tHcy was only weakly associated with blood pressure in a group of 972 people aged 65 years and over. 31 Dalery and colleagues determined plasma levels of homocysteine in 584 healthy French Canadian subjects (380 men and 204 women) and in 150 subjects (123 men and 27 women) with angiographically documented coronary artery disease (CAD) (age Ͻ60 years). No significant correlation was found between plasma homocysteine levels and the presence of hypertension in healthy subjects or in patients with CAD. 32 By contrast, in a small case-control study involving less than 400 older adults, Sutton-Tyrrell and colleagues found that fasting tHcy was significantly associated with isolated systolic hypertension. 33 Of course, absent or weak associations between homocysteine and blood pressure may simply reflect measurement error. In the Hordaland study for instance, homocysteine concentrations were measured in non-fasting samples and the blood pressure data based on the second of three measurements. There is an obvious need for additional studies to address this question including studies of the effect of folate supplements on blood pressure.
Conclusions
The findings from a further major meta-analysis of homocysteine and cardiovascular risk are expected with the next year (R Clarke, personal communication). Ultimately, data from randomised controlled trials will resolve the issue of whether raised tHcy concentrations are an important, modifiable risk factor for cardiovascular disease including stroke. It is likely that the data from these trials will show, at best, a modest independent effect of homocysteine on risk of stroke. However, given the high prevalence of hyperhomocysteinemia in apparently well nourished populations and the tendency for homocysteine concentrations to increase with age, modest effects on stroke risk will have profound implications for public health. 34 Thus for the homocysteine-vascular disease hypothesis at 30 years, the best may be yet to come!
